Karim Fizazi
Institut Gustave Roussy
770 Papers
3.2K Citations
Karim Fizazi is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 96, co-authored 658 publications. Previous affiliations of Karim Fizazi include Université Paris-Saclay & University College London.
Chat about Author
Papers
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Christopher J. Logothetis,Ethan Basch,Arturo Molina,Karim Fizazi,Scott North,Kim N. Chi,Robert Jones,Oscar B. Goodman,Paul N. Mainwaring,Cora N. Sternberg,Eleni Efstathiou,Dennis D. Gagnon,Margaret Rothman,Yanni Hao,Cameron S. Liu,Thian Kheoh,C. M. Haqq,Howard I. Scher,Johann S. de Bono +18 more
TL;DR: In patients with metastatic castration-resistant prostate cancer previously treated with docetaxel, abiraterone acetate and prednisone offer significant benefits compared withprednisone alone in terms of pain relief, delayed pain progression, and prevention of skeletal-related events.
287
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up
Friedemann Honecker,Jorge Aparicio,Daniel M. Berney,Jörg Beyer,Carsten Bokemeyer,Richard Cathomas,Noel W. Clarke,Gabriella Cohn-Cedermark,Gedske Daugaard,K-P Dieckmann,Karim Fizazi,Sophie D. Fosså,J R Germa-Lluch,Patrizia Giannatempo,Jourik A. Gietema,Silke Gillessen,Silke Gillessen,Hege Sagstuen Haugnes,Axel Heidenreich,Kari Hemminki,Robert Huddart,Michael A.S. Jewett,Florence Joly,Jakob Lauritsen,Anja Lorch,Andrea Necchi,Nicola Nicolai,Christoph Oing,Jan Oldenburg,D. Ondruš,Alexandros Papachristofilou,Thomas Powles,Aslam Sohaib,Olof Ståhl,T. Tandstad,Guy C. Toner,Alan Horwich +36 more
TL;DR: The aim of the conference was to develop detailed recommendations on topics relating to testicular cancer that are not covered in detail in the current ESMO Clinical Practice Guidelines (CPGs) and where the available level of evidence is insufficient.
286
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
Dana E. Rathkopf,Matthew R. Smith,Johann S. de Bono,Christopher J. Logothetis,Neal D. Shore,Paul de Souza,Karim Fizazi,Peter F.A. Mulders,Paul N. Mainwaring,John D. Hainsworth,Tomasz M. Beer,Scott North,Yves Fradet,Hendrik Van Poppel,Joan Carles,Thomas W. Flaig,Eleni Efstathiou,Evan Y. Yu,Celestia S. Higano,Mary-Ellen Taplin,Thomas W. Griffin,Mary B. Todd,Margaret K. Yu,Youn C. Park,Thian Kheoh,Eric J. Small,Howard I. Scher,Arturo Molina,Charles J. Ryan,Fred Saad +29 more
TL;DR: The updated IA of study COU-AA-302 in patients with mCRPC without prior chemotherapy confirms that abiraterone delays disease progression, pain, and functional deterioration and has clinical benefit with a favourable safety profile, including in patients treated for ≥24 mo.
279
Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients
Lisa Derosa,Bertrand Routy,Marine Fidelle,Valerio Iebba,Valerio Iebba,Laurie Alla,Edoardo Pasolli,Nicola Segata,Aude Desnoyer,Aude Desnoyer,Filippo Pietrantonio,Gladys Ferrere,Gladys Ferrere,Jean-Eudes Fahrner,Emmanuelle Le Chatellier,Nicolas Pons,Nathalie Galleron,Hugo Roume,Connie P.M. Duong,Connie P.M. Duong,Laura Mondragón,Laura Mondragón,Laura Mondragón,Kristina Iribarren,Mélodie Bonvalet,Mélodie Bonvalet,Safae Terrisse,Conrad Rauber,Conrad Rauber,Conrad Rauber,Anne-Gaëlle Goubet,Anne-Gaëlle Goubet,Anne-Gaëlle Goubet,Romain Daillère,Fabien Lemaitre,Anna Reni,Anna Reni,Beatrice Casu,Beatrice Casu,Maryam Tidjani Alou,Maryam Tidjani Alou,Carolina Alves Costa Silva,Carolina Alves Costa Silva,Didier Raoult,Karim Fizazi,Bernard Escudier,Guido Kroemer,Laurence Albiges,Laurence Albiges,Laurence Zitvogel +49 more
TL;DR: The composition of the microbiota is influenced by TKIs and ATBs, and impacts the success of immunotherapy, and future studies will help sharpen the role of these specific bacteria and their potential as new biomarkers.
265
Carcinoma of unknown primary (CUP)
Nicholas Pavlidis,Karim Fizazi +1 more
TL;DR: Molecular diagnosis with DNA microarrays demonstrates high sensitivity, but its prognostic contribution is still uncertain, and patients who belong to the non-favourable sub-sets have a worse prognosis.
255